Item 8.01. Other Events.
XOMA US LLC, a wholly owned subsidiary of XOMA Corporation (the "Company"),
continues to maintain its July 1, 2008, Amended and Restated Research,
Development and Commercialization Agreement with collaboration partner Novartis
for iscalimab. On August 27th 2021, Novartis shared with the Company that based
upon preliminary interim analysis results of Novartis' Phase 2b kidney
transplant study with iscalimab (CIRRUS I), Novartis intended to discontinue the
study. According to Novartis, the study would be discontinued due to
iscalimab-based treatment being less efficacious than tacrolimus-based treatment
in prevention of organ rejection in patients receiving a kidney transplant. At
the same time Novartis also confirmed it is continuing all other iscalimab
studies in indications other than kidney transplant, for example Sjögren's
Syndrome and Lupus Nephritis.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
XOMA CORPORATION 
